Market Overview

Morgan Stanley Upgrades Globus Medical, Expects 17% Upside

Share:
Morgan Stanley Upgrades Globus Medical, Expects 17% Upside
Related
Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Credit Suisse sees 18% upside in Abbott in premarket analyst action (Seeking Alpha)

Globus Medical Inc (NASDAQ: GMED), a medical device company that's among the major players in spine robotic surgery technologies, saw its stock gain more than 70 percent in 2017, and one analyst projects more upside in 2018. 

The Analyst

Morgan Stanley's Jonathan Demchick upgraded Globus Medical from Equal-Weight to Overweight with a price target boosted from $32 to $48.

The Thesis

Globus Medical's past two years were characterized by "more subdued" organic growth, but the company is on the verge of "significant" top-line acceleration, Demchick said in the upgrade note. (See the analyst's track record here.) 

This will be led by the company's emerging technology portfolio in both robotics and trauma, Demchick said.

Globus' opportunity is undervalued by investors, and the Street isn't accounting for the impact from implant pull-through, the analyst said. 

While robot-assisted surgery technology isn't necessarily new in areas like urology, gynecology and general surgery, Globus Medical's focus on the spine is new, the analyst said.

The adoption of robot-assisted spinal surgery is likely to grow given the following key benefits, Demchick said: 

  • Screw accuracy.
  • Less radiation
  • Fewer revisions.
  • A faster learning curve.

The Street understands that a company like Intuitive Surgical, Inc. (NASDAQ: ISRG) can generate $2,000 per incremental procedure; Globus Medical can generate $8,000 to $9,000, the analyst said. 

Globus Medical's stock is its trading at a 15.3x EV/EBITDA model on the analyst's 2018 estimates, which is "only a modest premium" to its small- and mid-cap medtech peers, which trade at a 15x multiple. A larger premium is warranted given the company's growth prospects and peer-leading tax benefits, Demchick said. 

Price Action

Shares of Globus Medical hit a new 52-week high of $43.07 on Tuesday and were trading higher by 5.43 percent at the time of publication. 

Related Links:

Globus Medical Stands On The Brink Of Inflection; Leerink Upgrades

Intuitive Surgical Details New Study That 'Provides Compelling And Valuable Evidence' On The Advantages Of Robotic-Assisted Surgery

Latest Ratings for GMED

DateFirmActionFromTo
Dec 2018Credit SuisseInitiates Coverage OnOutperform
Dec 2018Credit SuisseInitiates Coverage OnOutperform
Nov 2018UBSInitiates Coverage OnNeutral

View More Analyst Ratings for GMED
View the Latest Analyst Ratings

Posted-In: Jonathan Demchick Morgan StanleyAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (ISRG + GMED)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DESPKeyBancInitiates Coverage On0.0
MELIKeyBancInitiates Coverage On0.0
ALBKeyBancMaintains120.0
AVNSKeyBancMaintains67.0
ABTCredit SuisseInitiates Coverage On82.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

VIP Gamblers Push Down Macau's December Numbers

This Day In Market History: NYSE Volume Hits 20th Century Low